Related Experiment Video
Updated: Apr 30, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Renal lipidosis in patients enrolled in a methadone substitution program
Stefan Porubsky1, Christoph Kuppe, Tanja Maier
1From the Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany (Drs Porubsky and Gröne); the Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany (Dr Porubsky); the Department of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany (Drs Kuppe, Moeller, and Floege); the Department of Internal Medicine, University Hospital Giessen and Marburg, Marburg, Germany (Dr Maier); the Department of Internal Medicine, University Hospital Giessen and Marburg, Giessen, Germany (Dr Birk); and the Medical Clinic and Policlinic, University Hospitals LMU, Munich, Germany (Dr Wörnle). Drs Porubsky and Kuppe contributed equally to the manuscript.
Abstract:
Kidney biopsies often show accumulation of lipids or lipidlike material. Evidence has been provided that lipids can directly initiate and contribute to the progression of glomerular and tubulointerstitial lesions. In this study we describe a renal lipidosis occurring in patients with a positive history of narcotic abuse who were enrolled in a methadone substitution program. All 3 patients presented with proteinuria (2.5-20 g/d) and impaired renal function. Renal biopsy revealed a pronounced extracellular and intracellular deposition of lipidlike material in the glomerular, interstitial, and tubular compartments. Known causes of lipid storage could be excluded clinically and morphologically. We consider this to be a distinct renal lipidosis associated with narcotic abuse, methadone intake, or intravenous abuse thereof.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

